Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT02181413 |
Date of registration:
|
27/06/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
|
Scientific title:
|
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant |
Date of first enrolment:
|
July 1, 2014 |
Target sample size:
|
656 |
Recruitment status: |
Active, not recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT02181413 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Canada
|
Colombia
|
Czech Republic
|
Czechia
|
Denmark
|
France
|
Germany
|
Greece
|
Hungary
|
Israel
|
Italy
|
Japan
|
Korea, Republic of
|
Mexico
|
Netherlands
|
Norway
|
Poland
|
Portugal
|
Singapore
|
South Africa
|
Spain
|
Sweden
|
Switzerland
|
Taiwan
|
Thailand
|
Turkey
|
Ukraine
|
United Kingdom
|
United States
| | | | | | |
Contacts
|
Name:
|
Study Director |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Takeda |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
|